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Abstract:
Background:
Proper evidence-based classification and grading of a disease such as acne are important in guiding medical practitioners to properly diagnose
diseases and treat patients.
Objective:
This is a review of the present classification of acne in order to delineate modified approaches of acne treatment.
Methods:
The  available  literature  was  reviewed,  including  searches  from  7  databases  based  on  the  terms  “classification  of  acne  vulgaris  and
pathophysiology”,  according  to  evidence-based  medicine  using  the  Cochrane  risk  of  bias  tool.
Results:
From a total of 10,121 studies on acne classification, 51 full-text articles were assessed and 13 studies were included after screening for acne
classification.
Conclusion:
The  European-evidence-based  guideline  (EDF)  classification  fits  best.  We  propose  a  modified  classification  in  4  categories  to  improve  the
management of each stage of acne.
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1. INTRODUCTION
A usable and practical classification or grading system of
diseases is important both in medical practice and research. It
allows medical practitioners to treat diseases in an appropriate
and  effective  manner.  A  generally  accepted  grading  system
makes the comparison between different studies on the same
disease much easier.
Acne  vulgaris  is  a  chronic  inflammatory  disease  of  the
pilosebaceous  unit and  associated with  serious  consequences
* Address correspondence to this author at the Panrajdhevee Group, Bangkok,
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such as scar formation and a high psychological impact. There
are  multiple  factors  involved in  the  pathophysiology of  acne
vulgaris,  including  hormone-induced  sebum  production,
follicular hyper-keratinization and Propionibacterium acnes (P.
acnes)  inducing  inflammatory  mechanisms  (innate-  and
acquired  immunity).  P.  acnes  are  Gram-positive  anaerobic
bacteria that are found abundantly in the pilo-sebaceous unit of
the  skin  [1  -  3].  Epidermal  cells,  including  keratinocytes,
melanocytes  and  Langerhans  cells,  can  recruit  many
inflammatory  cells  such  as  neutrophils,  macrophages  and
natural  killer  cells  via  an  activated  innate  immunity  system,
which  explain  that  acne  is  an  inflammatory  disease  [4].
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Although many studies are performed in the last decades, acne
is still a complex and sometimes difficult to treat disease.
Multiple grading systems for acne have been proposed by
several groups of dermatologists since the 1930s. Among those
grading systems, 2 main methods of assessment were used: 1.
global severity grading and 2. lesion counting. The former is
based on the overall appearance that is divided into different
levels by comparison with the descriptive text or standardized
photography. The latter classifies based on the number of each
acne lesion and then multiplying the number of each type of
lesion by a given severity index. Both systems were reported
using numeric grading or sequential grading (mild, moderate,
and severe) [5 - 7]. Proper classification will assist clinicians
and  patients  in  determining  the  severity  of  the  disease  and
appropriate individual treatment [8].
The  purpose  of  this  review  is  to  evaluate  existing
classifications of acne and how they can best relate to diagnosis
and treatment.
2. OBJECTIVE
This  study  aims  to  review  existing  acne  classification
systems  and  their  relationship  with  a  rational  therapeutic
approach  to  diagnosis  and  treatment  of  acne  vulgaris.
3. MATERIALS AND METHODS
3.1. Search Methods
The  databases  of  PubMed,  Embase,  Scopus,  Web  of
Science,  Cochrane central  registry of  trials  (CENTRAL) and
Google Scholar were searched and documents collected until
the end of  September 2017.  The search terms “acne vulgaris
and  classification  and  pathophysiology”  were  assessed  using
the Cochrane risk of bias tool [9]. The articles were selected by
screening  the  title  and  the  abstract.  The  full  text  of  all  the
relevant articles was then assessed. The overall level of quality
of  evidence  was  assessed  using  the  Grading  of




The  search  found  10,121  articles  (Web  of  sciences  58,
Embase 389, PubMed 214, Medline (Ovid) 101, Cochrane 21,
Scopus 168, Google Scholar 9,170 articles) for acne vulgaris
classification and pathophysiology. 51 articles were assessed
for  the  full-  text.  There  were  13  full-  text  articles  after
screening  by  two  independent  investigators.
The exclusion criteria for full-text articles were articles on
diseases  other  than  acne  vulgaris,  not  relevant,  duplicate
publication  and  publication  in  a  language  other  than  the
English language. The details of the available classification are
presented in Table 1.
5. DISCUSSION
From  all  acne  classifications  that  were  reported  in  the
literature  over  the  past  20  years,  the  best  classification
regarding the grade of evidence (grade A) by the Grading of
Recommendation,  Assessment,  Development  and  Evaluation
(GRADE) approach was the one provided by Zaenglein et al.
[11],  and  European-evidence  based  guidelines  (EDF
guidelines)  [12].
Table 1. Details of available classifications over the period 1997-2017.
Reference Year Grade of
evidence
Classification/Grading of acne Discussion
Zaenglein et al [11]. 2016 A No universal acne grading/classifying system can
be recommended
  • Systematic review that was conducted by a
multidisciplinary team, including 17 experts in the field
of acne, 1 general practitioner, 1 pediatrician, and 1
patient
  • systematic search of evidence for 20 years and 242
abstracts were reviewed
Nast A. et al [12].
European evidence-
base guideline
2016 A Defined according to a global assessment
  • Comedonal acne: few comedones or no
inflammatory lesions
  • Mild to moderate papulopustular acne
(inflammatory lesions)
  • Severe papulopustular acne (inflammatory
lesions) and moderate nodular acne (nodules or
cysts)
  • severe nodular/conglobate acne(nodules or
cysts)
  • Systematic review that was developed in accordance
with the standard operating procedures of the European
Dermatology Forum
  • systematic search of evidence of 5 years and results
of 154 studies (28 from updated search) were compiled
by the experts with regard to clinical relevance




2015 C Defined according to a global evaluation of the
severity of acne lesions
  • Mild: few to several papules and pustules, no
nodule
  • Moderate: several to many papules and
pustules, few to many nodules
  • Severe: numerous or extensive papules and
pustules, many nodules
  • 13 leading dermatologists from six countries in SEA
(Hong Kong, India, Japan, Korea, Malaysia, the
Philippines, Singapore, Taiwan, Thailand and the USA)
adopt the ACC grading system for classification and
selection of treatment for acne patients
  • simple to use
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Reference Year Grade of
evidence
Classification/Grading of acne Discussion
Dréno et al [14].
Global Evaluation
Acne (GEA) scale
2011 C Defined according to a global evaluation of the
severity of acne lesions
  • Grade 0: Clear. No lesion
  • Grade 1: Almost clear. Almost no lesions (a
few scattered open or closed comedones and very
few papules)
  • Grade 2: Mild (easily recognizable: less than
half of the face is involved. A few open or closed
comedones and a few papules and pustules)
  • Grade 3: Moderate (more than half of the face
is involved; many papules and pustules; many
open or closed comedones; one nodule may be
present)
  • Grade 4: Severe (entire face is involved,
covered with many papules and pustules, open or
closed comedones and rare nodules)
  • Grade 5: Very severe (highly inflammatory
acne covering the face with the presence of
nodules)
  • Developed by 7 expert dermatologists in the field of
acne
  • small number of subjects (22 patients)
  • Difficult to recognize all the details of grading system
  • Training is needed for accurate grading
Hayashi et al. [24] 2008 C Defined according to the number of inflammatory
eruptions on half of the face
  • Mild: 0-5
  • Moderate: 6-20
  • Severe: 21–50
  • Very severe: >50
  • Evidence-based classification that was developed by
groups of dermatologists from 13 Universities and 3
independent expert dermatologists in Japan
  • Large number of subjects (244 patients)
  • Using lesion counting, lesion identification and
patient’s photography
  • Only inflammatory eruptions were involved in
grading
Sinclair et al [15]. 2005 C Defined according to the most severe lesions
  • Grade 1: Comedones only
  • Grade 2: Inflammatory papules present in
addition to the comedones
  • Grade 3: Pustules present in addition to any of
the above
  • Grade 4: Nodules, cysts, conglobate lesions or
ulcers present in addition to any of the above
  • Consensus of a group of about 40 experts in the field
of acne, mainly South African dermatologists
  • Sponsored by Galderma
  • No lesion count
The latter classified acne in 4 categories; comedonal acne
(open/closed  comedones),  mild  to  moderate  papulopustular
acne (superficial inflammatory lesions), severe papulopustular
acne  and  moderate  nodular  acne,  severe  nodular/conglobate
acne, which helped in the management of the acne correlated
with  the  disease  activity.  The  former  concluded  that  no
universal  acne  classification  could  be  recommended.  In  this
review, the European Dermatology Forum (EDF) guideline is
considered as the most appropriate guideline for acne treatment
among all  existing classifications. However,  it  relies only on
the  overall  severity  of  the  disease.  This  classification  is,
therefore, not useful for grading individual lesions. Different
lesions  can  be  in  a  different  stage  of  development  of
inflammation,  which  is  very  characteristic  of  acne.  For
research, the development of a single lesion during treatment is
important,  because  different  stages  of  inflammation  could
require  different  treatment  options.
An international consensus from the Global Alliance points
out  that  “There  is  no  standardized  acne  grading  or
classification system” [16]. However, there is a dire need for a
universal, easy and reliable classification system for acne. An
appropriate treatment should be related to pathology, which is
clinically seen based on the type of lesions. If the classification
corresponds  well  to  the  underlining  pathology,  a  treatment
algorithm  can  be  developed  on  the  basis  of  the  clinically
obtained classification. Therefore, a classification based on the
clinical  presentation  (of  the  type  of  acne  lesions)  with
consequences  of  therapy  would  contribute  to  an  ideal
classification.
Acne vulgaris is well recognized as an androgen-dependent
disease  of  the  pilosebaceous  unit  of  the  skin  [8].  The  main
factors involved in the pathogenesis of acne include hormonal
involvement, abnormal keratinization, colonization of P. acnes,
sebum production, and inflammatory events. All these factors
are widely accepted as being involved in the pathogenesis of
acne  vulgaris.  Finally,  the  clinical  lesions  are  a  reflection  of
inflammation; both the innate and the acquired immune system
play an important  role.  The involvement of toll-like receptor
2(TLR2) in stimulating inflammatory pathways activation and
inducing  monocytes  to  produce  IL-8  cytokine  is  through  the
peptidoglycan  on  gram-positive  bacterial  cell  wall  of  the  P.
acnes  [17].  Activation  of  NF-kβ  through  the  myeloid
differentiation  protein  (MyD88)  associated  kinase  is  the
intracellular signaling pathway of TLR2 and TLR4 [4, 18]. The
severity of inflammation may be related to the different types
of P. acnes, as shown in the study by Dagnelie et al. [19]. This
study presented evidence that helped conclude that P. acnes are
a  part  of  the  normal  flora  on  the  skin  and  can  activate  the
human innate immune system through TLRs by monocytes and
keratinocytes. P. acnes can be divided into 6 phylotypes (IA1,
IA2,  IB,  IC,  II  and  III),  whereby  each  different  strain  may
induce a different immune response. They investigated patients
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with  severe  acne  on  the  face  and  on  the  back  and  healthy
controls. In patients with acne, phylotype IA1 was predominant
(84.4%), especially in those with acne on the back (95.6%). In
71.4% of patients with severe acne, P.  acne phylotypes were
identical on the face and on the back, whereas this was the case
in only 45.5% of the healthy controls. They reported that the
severity  of  acne  was  associated  with  the  loss  of  P.  acnes
phylotypes  [19,  20].
Based on this review, the EDF guideline can be modified.
We  suggest  a  classification  based  on  each  stage  of  an  acne
lesion:
Acne type 1; skin color dome shape papule or comedone,
Acne type 2; moderate inflamed acne with faint red or pink
papule,
Acne type 3; red papule, papulopustular lesion,
Acne type 4; nodule, nodulocystic, and cystic lesion. See
Fig. 1. and Table 2.
All  clinical  lesions  of  acne  vulgaris  are  now  considered
inflammatory  lesions,  regardless  of  whether  there  is  any
clinical  sign  of  inflammation  [3].  The  biopsy  from the  early
stage  of  acne  shows  the  feature  of  a  lymphoid  perivascular
infiltrate.  There  is  evidence  that  in  the  early  stage  of  acne,
lymphocytes  and  macrophages  infiltrate  hair  follicle  and
release  many  inflammatory  cytokines  (IL-2,  TNFα,  IL-10,
IGF1,  TGFα,  TGFβ,  KGF,  PDGF,  etc.)  [21].  Lytic  enzymes
and  lipases  released  from  P.  acnes  produce  follicular
epithelium disruption leading to inflammation of the acne [1].
In late stage acne, there is a neutrophilic response and myeloid
cells  phagocytize  P. acnes  in  the dermis  via  the chemotactic
factors [1, 22]. Polymorphonuclear leukocytes (PMN) infiltrate
in the lesion, lead to pustule formation and cause rupture of the
lesion [3, 4]. The inflammatory cytokines cause vasodilation of
vessels  and  melanogenesis  [21].  Histologically,  there  are
differences in the cell types that are located at different depths
and also different sites and different severity of ruptures of the
affected infundibular wall as shown in Fig. (2).
The  appropriate  clinical  criteria  should  start  from  the
sequence of acne development. The stage of acne starts from
mild to moderate and severe inflammation. Mild and moderate
lesions usually resolve without any consequences such as post-
inflammatory erythema or hyperpigmentation. While a severe
acne lesion almost always is followed by a complication. Acne
guideline recommends to scale the acne lesions of the whole
face,  applying  every  anti-acne  product  on  the  whole  face  or
prescribing the systemic medication. The research and practice
from  Linda  S  Gold  et  al.  [23],  addressed  that  “it  is  very
uncommon for inflammatory and non-inflammatory lesions to
respond to an acne therapy in the same fashion over the same
timeframe “.  We have noticed that each type of lesion is not
only  clinically  different  but  also  there  are  differences  and
similarities  in  their  histology,  immuno  histochemistry  of  the
inflammatory  cell  infiltration,  the  wall  of  the  pilosebaceous
apparatus and inflammatory reaction, as summarized in Table
3. So they may share the same kind of therapy and they should
be treated differently dependable on future discovery.
Fig (1). Clinical features of acne vulgaris. (a) Acne type 1 lesion (b) Acne type 2 lesion (c) Acne type 3 (d) Acne type 4
Acne type 1, mildly inflamed papular lesions
Acne type 2, moderately inflamed, pink papules
Acne type 3, fully blown inflamed, red papulopustules
Acne type 4, deep-seated papules or nodulocystic.
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Fig. (2). Histological features of acne type 3 with Hematoxylin and eosin stain (H&E stain).(a). Dense inflammatory infiltrate around and within
ductal epithelium and canal (H&E, x10) (b). Partial destruction of ductal wall with comedone plugging, infiltrate of neutrophils within ruptured wall
(H&E, x40) (c). Dense infiltrate of neutrophils around clumps of Gram-positive bacteria and cornified material (H&E,x40).
Table 2. Clinical presentation of acne vulgaris comparison between two classifications.
New Classfication Clinical Presentation European Evidence-Based Guideline (EDF)
Acne type 1 skin color dome shape papule or comedone Comedonal acne
Acne type 2 moderate inflamed acne with faint red or pink papule Mild to moderate papulopustular acne
Acne type 3 red papule, papulopustular lesion Severe papulopustular acne and moderate nodular acne
Acne type 4 nodule, nodulocystic, and cystic lesion severe nodular/conglobate acne
Table 3. Summary of histology, immunochemistry, type of inflammation and therapeutic rationales.
Type of Lesion Histology / Immunohistochemistry Type of Inflammation Therapeutic Rationales
Cell Inflammation Pilosebaceous Apparatus TLR2 TLR4 Major Rx Adjunctive Rx




Positive Mostly negative Comedone
extraction
Anti TLR2
Type 2 moderate Lymphocyte and monocyte
no neutrophil
Minor rupture of upper part Positive Mostly negative Anti TLR2 -








There  are  multiple  favorable  acne  classifications;  this
evidence-based  search  gives  an  advice  that  among  all  the
classifications,  the  EDF  fits  best.  However,  none  of  them
classified acne by each individual stage of acne lesions and its
root  cause.  The  suggested  improved  classification  should  be
able to combine clinical, molecular biological and histological
features,  which  may  lead  to  improved  identification  and
management  of  each  stage  of  acne.
LIST OF ABBREVIATION
CENTRAL = CENTRAL Cochrane central registry of trial
EDF guidelines = European-evidence based guidelines
GEA = Global Evaluation Acne scale
GRADE = Grading  of  Recommendation,  Assessment,
Development  and  Evaluation
MyD88 = Myeloid differentiation protein
P. acnes = Propionibacterium acnes
TLR2 = Toll-like receptor 2
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